These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 23975081)

  • 41. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
    Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.
    Wu SY; Huang EY; Chanchien CC; Lin H; Wang CJ; Sun LM; Chen HC; Fang FM; Hsu HC; Huang YJ
    J Radiat Res; 2014 Jan; 55(1):129-38. PubMed ID: 23814113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation study.
    Macchia G; Cilla S; Deodato F; Legge F; Di Stefano A; Chiantera V; Scambia G; Valentini V; Morganti AG; Ferrandina G
    Br J Radiol; 2015; 88(1055):20150385. PubMed ID: 26388108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.
    Phung HT; Truong MC; Nguyen LT; Dang ATV; Vu TH; Nguyen HT
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):853-859. PubMed ID: 33773550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Added value of para-aortic surgical staging compared to
    De Cuypere M; Lovinfosse P; Goffin F; Gennigens C; Rovira R; Duch J; Fastrez M; Gebhart G; Squifflet JL; Luyckx M; Charaf G; Crener K; Buxant F; Bucella D; Jouret M; Hustinx R; Kridelka F
    Eur J Surg Oncol; 2020 May; 46(5):883-887. PubMed ID: 31784203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IMRT with ¹⁸FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer.
    Cihoric N; Tapia C; Krüger K; Aebersold DM; Klaeser B; Lössl K
    Radiat Oncol; 2014 Mar; 9():83. PubMed ID: 24661323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
    Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
    Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
    Schwarz JK; Wahab S; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1258-63. PubMed ID: 20932657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
    Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer.
    Ramlov A; Kroon PS; Jürgenliemk-Schulz IM; De Leeuw AA; Gormsen LC; Fokdal LU; Tanderup K; Lindegaard JC
    Acta Oncol; 2015; 54(9):1567-73. PubMed ID: 26271799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.
    Chen MF; Tseng CJ; Tseng CC; Yu CY; Wu CT; Chen WC
    Cancer J; 2008; 14(3):200-6. PubMed ID: 18536561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early clinical outcome of coverage probability based treatment planning for simultaneous integrated boost of nodes in locally advanced cervical cancer.
    Lindegaard JC; Assenholt M; Ramlov A; Fokdal LU; Alber M; Tanderup K
    Acta Oncol; 2017 Nov; 56(11):1479-1486. PubMed ID: 28849684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Extended-field intensity modulated radiation therapy and intra-cavitary brachytherapy combined with chemotherapy for stage Ib1-IVa cervical cancer with positive para-aortic lymph nodes].
    Ke GH; Huang X; Huang XW; Liu SP; Wu XH
    Zhonghua Fu Chan Ke Za Zhi; 2013 Sep; 48(9):649-53. PubMed ID: 24332129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area.
    Boughanim M; Leboulleux S; Rey A; Pham CT; Zafrani Y; Duvillard P; Lumbroso J; Haie-Meder C; Schlumberger M; Morice P
    J Clin Oncol; 2008 May; 26(15):2558-61. PubMed ID: 18487573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer.
    Chou HH; Huang HJ; Lin H; Yang LY; Hsueh S; Liu FY; Liou YL; Liou JD; Chen MY; Chao A; Lin G; Chang TC; Lai CH
    Am J Clin Oncol; 2017 Jun; 40(3):241-249. PubMed ID: 25350466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: a randomized controlled trial.
    Punushapai U; Yuenyao P; Chumworathayi B; Luanratanakorn S; Udomthavornsuk B
    Asian Pac J Cancer Prev; 2010; 11(1):201-7. PubMed ID: 20593957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
    Huang J; Gu F; Ji T; Zhao J; Li G
    Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
    Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.